Stroke and thromboembolism in atrial fibrillation.
暂无分享,去创建一个
Ron Pisters | A. Camm | D. Lane | F. Marín | R. Pisters | G. Lip | A John Camm | Deirdre A Lane | Gregory Y H Lip | Francisco Marin
[1] Gregory Y H Lip,et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. , 2010, Chest.
[2] A. Mcguire,et al. Cost-effectiveness of anticoagulation in nonrheumatic atrial fibrillation in the primary prevention of ischemic stroke. , 1998, Stroke.
[3] G. Lip,et al. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study , 2012, BMJ : British Medical Journal.
[4] G. Lowe,et al. ABC of Atrial Fibrillation: ANTITHROMBOTIC TREATMENT FOR ATRIAL FIBRILLATION , 1996, BMJ.
[5] S. Pauker,et al. Making decisions about antithrombotic therapy in heart disease. Decision analytic and cost-effectiveness issues. , 1998, Chest.
[6] A. Hofman,et al. A longitudinal population‐based study of prothrombotic factors in elderly subjects with atrial fibrillation: the Rotterdam Study 1990–1999 , 2006, Journal of thrombosis and haemostasis : JTH.
[7] B. Gage,et al. Selecting Patients With Atrial Fibrillation for Anticoagulation: Stroke Risk Stratification in Patients Taking Aspirin , 2004, Circulation.
[8] J. Kluger,et al. Cost-Effectiveness of Apixaban Compared With Aspirin for Stroke Prevention in Atrial Fibrillation Among Patients Unsuitable for Warfarin , 2012, Circulation. Cardiovascular quality and outcomes.
[9] M. Overgaard,et al. Cost-effectiveness of dabigatran etexilate for stroke prevention in non-valvular atrial fibrillation. Applying RE-LY to clinical practice in Denmark , 2012, Journal of medical economics.
[10] A. Tjønneland,et al. Impact of vascular disease in predicting stroke and death in patients with atrial fibrillation: the Danish Diet, Cancer and Health cohort study , 2011, Journal of thrombosis and haemostasis : JTH.
[11] J. Kluger,et al. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. , 2012, The American journal of cardiology.
[12] M. Aguilar,et al. Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.
[13] R. Cheung. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. , 1998, JAMA.
[14] William C. Cockerham. Physicians , 2001, BMJ : British Medical Journal.
[15] Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. , 1994, Archives of internal medicine.
[16] A R Feinstein,et al. Risk for systemic embolization of atrial fibrillation without mitral stenosis. , 1990, The American journal of cardiology.
[17] Steven J Edwards,et al. Stroke prevention with aspirin, warfarin and ximelagatran in patients with non-valvular atrial fibrillation: a systematic review and meta-analysis. , 2006, Thrombosis research.
[18] D. Singer,et al. Antithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. , 2004, Chest.
[19] R. de Caterina,et al. Risks and Benefits of Oral Anticoagulation Compared With Clopidogrel Plus Aspirin in Patients With Atrial Fibrillation According to Stroke Risk: The Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE-W) , 2008, Stroke.
[20] M. Prins,et al. Feasibility of TEE-guided stroke risk assessment in atrial fibrillation—background, aims, design and baseline data of the TIARA pilot study , 2011, Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation.
[21] G. Lip,et al. Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial , 2011, BMJ : British Medical Journal.
[22] A. Waldo,et al. Chronic atrial fibrillation: Incidence, prevalence, and prediction of stroke using the Congestive heart failure, Hypertension, Age >75, Diabetes mellitus, and prior Stroke or transient ischemic attack (CHADS2) risk stratification scheme , 2009 .
[23] L. Frost,et al. Age and Risk of Stroke in Atrial Fibrillation: Evidence for Guidelines? , 2007, Neuroepidemiology.
[24] D. Singer,et al. Impact of Proteinuria and Glomerular Filtration Rate on Risk of Thromboembolism in Atrial Fibrillation: The Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study , 2009, Circulation.
[25] L. Pearce. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: The stroke prevention in atrial fibrillation study. , 1995, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.
[26] W. Aronow,et al. Risk factors for thromboembolic stroke in elderly patients with chronic atrial fibrillation. , 1989, The American journal of cardiology.
[27] G. Lip,et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial , 2007, The Lancet.
[28] D. Singer,et al. Gender Differences in the Risk of Ischemic Stroke and Peripheral Embolism in Atrial Fibrillation: The AnTicoagulation and Risk factors In Atrial fibrillation (ATRIA) Study , 2005, Circulation.
[29] Gregory Y H Lip,et al. Stroke and thromboembolism in atrial fibrillation: A systematic review of stroke risk factors, risk stratification schema and cost effectiveness data , 2008, Thrombosis and Haemostasis.
[30] M. Rosenqvist,et al. Stroke in paroxysmal atrial fibrillation: report from the Stockholm Cohort of Atrial Fibrillation. , 2010, European heart journal.
[31] A. Algra,et al. Predictors of major vascular events in patients with a transient ischemic attack or minor ischemic stroke and with nonrheumatic atrial fibrillation. European Atrial Fibrillation Trial (EAFT) Study Group. , 1995, Stroke.
[32] G. Breithardt,et al. Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[33] Paul Robinson,et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation , 2012, Heart.
[34] V. Fuster,et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation , 2001 .
[35] L. Køber,et al. Vascular disease and stroke risk in atrial fibrillation: a nationwide cohort study. , 2012, The American journal of medicine.
[36] U. Ikeda,et al. Mitral regurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation. , 1998, American heart journal.
[37] D. Lane,et al. A comparison of risk stratification schemes for stroke in 79 884 atrial fibrillation patients in general practice , 2011, Journal of thrombosis and haemostasis : JTH.
[38] Daniel Levy,et al. Arrhythmias: abstractA risk score for predicting stroke or death in individuals with new-onset atrial fibrillation in the community. The Framingham Heart Study☆ , 2003 .
[39] G. Lip,et al. Reliable Identification of “Truly Low” Thromboembolic Risk in Patients Initially Diagnosed With “Lone” Atrial Fibrillation: The Belgrade Atrial Fibrillation Study , 2012, Circulation. Arrhythmia and electrophysiology.
[40] Jeroen J. Bax,et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. , 2012, European heart journal.
[41] J. Halperin,et al. Assessment of three schemes for stratifying stroke risk in patients with nonvalvular atrial fibrillation. , 2000, The American journal of medicine.
[42] B. Norrving,et al. Cost effectiveness of primary stroke prevention in atrial fibrillation: Swedish national perspective. , 1992, BMJ.
[43] G. Samsa,et al. Cost Efficiency of Anticoagulation With Warfarin to Prevent Stroke in Medicare Beneficiaries With Nonvalvular Atrial Fibrillation , 2011, Stroke.
[44] G. Lip,et al. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. , 2007, QJM : monthly journal of the Association of Physicians.
[45] J. Senges,et al. Risk of thromboembolic events in patients with atrial flutter. , 1998, The American journal of cardiology.
[46] Samuel Wann,et al. ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committ , 2006, European heart journal.
[47] A. Hofman,et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. , 2006, European heart journal.
[48] Donald R. Lynch. Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[49] Yuchiao Chang,et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? , 2003, JAMA.
[50] Gregory Y H Lip,et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. , 2011, Journal of the American College of Cardiology.
[51] D K Owens,et al. Cost-effectiveness of warfarin and aspirin for prophylaxis of stroke in patients with nonvalvular atrial fibrillation. , 1995, JAMA.
[52] Leon Poller,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[53] W. Aronow,et al. Risk factors for new thromboembolic stroke in patients > or = 62 years of age with chronic atrial fibrillation. , 1998, The American journal of cardiology.
[54] S. Connolly,et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspective , 2011, Thrombosis and Haemostasis.
[55] Apixaban versus Warfarin in Patients with Atrial Fibrillation , 2012 .
[56] G. Breithardt,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[57] R. Thomson,et al. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation , 2000, The Lancet.
[58] D. Singer,et al. Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation: The Atrial Fibrillation Investigators , 2009, Stroke.
[59] N. Desbiens. Deciding on Anticoagulating the Oldest Old with Atrial Fibrillation: Insights from Cost‐Effectiveness Analysis , 2002, Journal of the American Geriatrics Society.
[60] Jeroen J. Bax,et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). , 2010, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[61] Gregory Y H Lip,et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. , 2010, Chest.
[62] A. Banerjee,et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study , 2011, Thrombosis and Haemostasis.
[63] J. Kastrup,et al. Risk factors for thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. , 1990 .
[64] G. Lip,et al. Atrial fibrillation and upper limb thromboembolectomy: a national cohort study , 2011, Journal of thrombosis and haemostasis : JTH.
[66] R. Hart. Stroke prevention in atrial fibrillation , 2000, Current cardiology reports.
[67] E. Rahme,et al. Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation. , 2012, JAMA.
[68] A. Laupacis,et al. A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin. , 2003, Archives of internal medicine.
[69] G. Lip,et al. Predictive value of the HAS-BLED and ATRIA bleeding scores for the risk of serious bleeding in a 'real world' anticoagulated atrial fibrillation population. , 2012 .
[70] J. Finsterer,et al. Mortality and rate of stroke or embolism in atrial fibrillation during long‐term follow‐up in the embolism in left atrial thrombi (ELAT) study , 2004, Clinical cardiology.
[71] D. Singer,et al. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. , 2011, Journal of the American College of Cardiology.
[72] D. Levy,et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. , 1998, Circulation.
[73] M. Wallander,et al. Risk of cardiovascular and cerebrovascular events after atrial fibrillation diagnosis. , 2009, International journal of cardiology.
[74] J. Tolstrup,et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study , 2011, BMJ : British Medical Journal.
[75] M. Brainin,et al. Transesophageal Echocardiography To Assess Embolic Risk in Patients with Atrial Fibrillation , 1998, Annals of Internal Medicine.
[76] H. Inoue,et al. Risk factors for thromboembolism in patients with paroxysmal atrial fibrillation. , 2000, The American journal of cardiology.
[77] J. Plumb,et al. Risks of stroke and mortality associated with suboptimal anticoagulation in atrial fibrillation patients , 2011, Thrombosis and Haemostasis.
[78] Samuel Wann,et al. [Guidelines for the management of patients with atrial fibrillation. Executive summary]. , 2006, Revista espanola de cardiologia.
[79] D. Singer,et al. Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study. , 1991, The American journal of medicine.
[80] R. P. Zhu,et al. Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Atrial Fibrillation , 2011, Annals of Internal Medicine.
[81] Lian-Yu Lin,et al. Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation-- a nation wide database analysis. , 2011, Atherosclerosis.
[82] D. Singer,et al. Cost-effectiveness of warfarin: trial versus "real-world" stroke prevention in atrial fibrillation. , 2009, American heart journal.
[83] R McBride,et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. , 1999, Stroke.
[84] B. Gage,et al. Cost-Effectiveness of Dabigatran for Stroke Prophylaxis in Atrial Fibrillation , 2010, Circulation.
[85] Munir Pirmohamed,et al. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses , 2011, BMJ : British Medical Journal.
[86] G. Lip,et al. Risk factors for stroke and thromboembolism in relation to age among patients with atrial fibrillation: the Loire Valley Atrial Fibrillation Project. , 2012, Chest.
[87] G. Guyatt,et al. The sixth (2000) ACCP guidelines for antithrombotic therapy for prevention and treatment of thrombosis. American College of Chest Physicians. , 2001, Chest.
[88] J. Halperin,et al. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. , 2000, Journal of the American College of Cardiology.
[89] J. Tolstrup,et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: A net clinical benefit analysis using a ‘real world’ nationwide cohort study , 2011, Thrombosis and Haemostasis.
[90] Stirling Bryan,et al. Cost Effectiveness of Warfarin Versus Aspirin in Patients Older Than 75 Years With Atrial Fibrillation , 2011, Stroke.
[91] Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. , 1998, Archives of internal medicine.
[92] Martha J. Radford,et al. Validation of Clinical Classification Schemes for Predicting Stroke: Results From the National Registry of Atrial Fibrillation , 2001 .
[93] L. Fauchier,et al. Antithrombotic treatment and the risk of death and stroke in patients with atrial fibrillation and a CHADS2 score=1 , 2010, Thrombosis and Haemostasis.